November 6, 2006 -- Abbott Labs offered $78 per share for Kos Pharma, a 56% premium to its previous price; Adolor and GlaxoSmithKline received an Approvable letter for Entereg, their treatment for postoperative ileus; MedImmune said Numax, a respiratory syncytial virus drug, met its endpoint; CombinatoRx announced CRx-102 was effective against rheumatoid arthritis; Indevus Pharma out-licensed the ex-US rights to Sanctura XR, an overactive bladder drug; Alnylam published data from an animal study showing success with an RNAi therapeutic; Cell Therapeutics put a temporary hold on new enrolments in a lung cancer trial of Xyotax; Medarex reported resignations in the wake of an options-backdating scandal; Accentia will begin a Phase III trial for SinuNase, a treatment for sinusitis; and Geron signed an exclusive license with Immunomic Therapeutics for an antigen targeting sequence. The Centient Biotech 200™ rose 55 points to 3988, an increase of 1.41%. More details...
